Literature DB >> 19191180

Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population.

Alessandro Lambiase1, Simona Minchiotti, Andrea Leonardi, A G Secchi, Maurizio Rolando, Giovanni Calabria, Jelka Orsoni, Enrica Zola, Giuseppe Ferreri, Pasquale Aragona, Alfredo Reibaldi, Giorgio Chisari, Stefano Bonini.   

Abstract

PURPOSE: To evaluate the frequency and epidemiological features of vernal keratoconjunctivitis (VKC) in Italy.
METHODS: a specific electronic clinical chart for vernal keratoconjunctivitis was created to standardize: 1) medical history; 2) diagnostic criteria; 3) signs and symptoms; and 4) treatments. This study involved 6 Italian referral centers for ocular surface diseases: between March 2005 and March 2006, all referred patients were included, clinical data collected and statistically examined.
RESULTS: The mean age of the vernal keratoconjunctivitis population (n = 156) was 13.8 +/- 8.8 with 64.1% of subjects under 14 years of age and a male/female ratio of 3.5:1. Among VKC patients, 48.7% showed associated systemic allergic diseases. Only 32.1% of patients were positive for RAST and/or prick test. The limbal form (53.8%) was the most frequent subtype of vernal keratoconjunctivitis. Approximately 9% of patients showed a severe form of vernal keratoconjunctivitis. At the first visit patients were treated with: multiple action or mast cell stabilizer eye drops (58.1% and 41.3% of cases, respectively), topical corticosteroids alone (0.6%) or in association (26.8% of cases). All patients used topical steroids at least once in the studied year. Systemic antihistamine therapy was used by 25.6% of patients. In this cohort, 32.7% of patients required two or more examinations per year for exacerbations of their symptoms.
CONCLUSION: Vernal keratoconjunctivitis is a severe ocular condition that mainly affects young males. Vernal keratoconjunctivitis is characterized by different clinical features and therapeutic responses, suggesting the need for a standardized therapeutic approach on the basis of a grading of disease severity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191180     DOI: 10.1080/09286580802573177

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  15 in total

1.  Vernal keratoconjunctivitis in school children in Rwanda and its association with socio-economic status: a population-based survey.

Authors:  Stefan De Smedt; John Nkurikiye; Yannick Fonteyne; Arjan Hogewoning; Marjan Van Esbroeck; Dirk De Bacquer; Stephen Tuft; Clare Gilbert; Joris Delanghe; Philippe Kestelyn
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

Review 2.  Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.

Authors:  Pakit Vichyanond; Panida Kosrirukvongs
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

3.  Vernal Keratoconjunctivitis in Kashmir: A temperate zone.

Authors:  Rayees Ahmad Sofi; Asmat Mufti
Journal:  Int Ophthalmol       Date:  2016-03-10       Impact factor: 2.031

4.  Ocular complications of severe vernal keratoconjunctivitis (VKC) in Yemen.

Authors:  Saleh A Al-Akily; Mahfouth A Bamashmus
Journal:  Saudi J Ophthalmol       Date:  2011-02-16

5.  Quiescent and Active Tear Protein Profiles to Predict Vernal Keratoconjunctivitis Reactivation.

Authors:  Alessandra Micera; Antonio Di Zazzo; Graziana Esposito; Roberto Sgrulletta; Virginia L Calder; Stefano Bonini
Journal:  Biomed Res Int       Date:  2016-02-17       Impact factor: 3.411

6.  Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre.

Authors:  Sukriti Gupta; Priyanka Singh; Mrityunjay Singh; Mayuresh Naik; Kartikeya Srivastava
Journal:  Clin Ophthalmol       Date:  2021-07-14

Review 7.  Potential Biomarkers for Allergic Conjunctival Diseases.

Authors:  Neeta Roy; Shir Levanon; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2020-03       Impact factor: 3.152

8.  Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India.

Authors:  Ujwala S Saboo; Manish Jain; Jagadesh C Reddy; Virender S Sangwan
Journal:  Indian J Ophthalmol       Date:  2013-09       Impact factor: 1.848

9.  Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement.

Authors:  Atsuki Fukushima; Yuichi Ohashi; Nobuyuki Ebihara; Eiichi Uchio; Shigeki Okamoto; Naoki Kumagai; Jun Shoji; Etsuko Takamura; Yayoi Nakagawa; Kenichi Namba; Hiroshi Fujishima; Dai Miyazaki
Journal:  Br J Ophthalmol       Date:  2014-04-02       Impact factor: 4.638

10.  Dry Eye in Vernal Keratoconjunctivitis: A Cross-Sectional Comparative Study.

Authors:  Edoardo Villani; Marika Dello Strologo; Francesco Pichi; Saverio V Luccarelli; Stefano De Cillà; Massimiliano Serafino; Paolo Nucci
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.